Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer

Autor: Oh, Jonathan, Barve, Minal, Matthews, Carolyn M., Koon, E. Colin, Heffernan, Thomas P., Fine, Bruce, Grosen, Elizabeth, Bergman, Melanie K., Fleming, Evelyn L, DeMars, Leslie R., West, Loyd, Spitz, Daniel L., Goodman, Howard, Hancock, Kenneth C., Wallraven, Gladice, Kumar, Padmasini, Bognar, Ernest, Manning, Luisa, Pappen, Beena O., Adams, Ned, Senzer, Neil, Nemunaitis, John
Zdroj: In Gynecologic Oncology December 2016 143(3):504-510
Databáze: ScienceDirect
Externí odkaz: